<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<doc>
  <docno>
    <textblock>FR940207-2-00090</textblock>
  </docno>
  <parent>
    <textblock>FR940207-2-00040</textblock>
  </parent>
  <text>
    <textblock>Notice is hereby given of the NIH Consensus Development Conference on ``Effects of Corticosteroids for Fetal Maturation on Perinatal Outcomes,'' which will be held February 28-March 2, 1994, in the Masur Auditorium of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. This conference is sponsored by the National Institute of Child Health and Human Development and the NIH Office of Medical Applications of Research. The conference is cosponsored by the National Heart, Lung, and Blood Institute and the National Institute of Nursing Research. The conference begins at 8:30 a.m. on February 28, 8 a.m. on March 1, and 9 a.m. on March 2. The meeting is open to the public at no charge.</textblock>
    <textblock>One of a series of NIH Consensus Development Conferences, this conference will evaluate the data available related to antenatal corticosteroid treatment of pregnant women delivering prematurely. The conditions and purposes of this treatment will be reviewed, as well as its short-term and long-term benefits and adverse effects. In addition, the economic consequences of this treatment will be considered.</textblock>
    <textblock>After 11/2 days of presentations and discussion by the audience, an independent non-Federal consensus panel will weigh the scientific evidence and write a draft consensus statement in response to the following key questions:</textblock>
    <textblock>•For what conditions and purposes are antenatal corticosteroids used, and what is the scientific basis for that use?</textblock>
    <textblock>•What are the short-term and long-term benefits of antenatal corticosteroid treatment?</textblock>
    <textblock>•What are the short-term and long-term adverse effects for the infant and mother?</textblock>
    <textblock>•What are the economic consequences of this treatment?</textblock>
    <textblock>•What is the influence of type of corticosteroid, dosage, timing and circumstances of administration, and associated therapy on treatment outcome?</textblock>
    <textblock>•What are the recommendations for use of antenatal corticosteroids?</textblock>
    <textblock>•What research is needed to guide clinical care?</textblock>
    <textblock>On the final day of the meeting, the consensus panel chairman will read the draft statement to the conference audience and invite comments and questions.</textblock>
    <textblock>Advance information on the conference program and conference registration materials may be obtained from: Debra Steward, Technical Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland 20852, phone (301) 770-3153.</textblock>
    <textblock>A draft report will be prepared before the conference by the consensus panel, providing preliminary information on the issues described above. Advance copies of this report will be available to the public by January 15, 1994. Interested persons or organizations may obtain a copy of this draft report from: Debra Steward, Technical Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland 20852, phone (301) 770-3153.</textblock>
    <textblock>Those individuals wishing to make comments on the draft report may submit their comments in writing by February 14, 1994, to Mr. Jerry Elliott, Office of Medical Applications of Research, National Institutes of Health, Federal Building, Room 618, Bethesda, Maryland 20892. Individuals may also present their comments during discussion periods at the conference. Written comments and discussion at the conference will be used to prepare the final panel report, which will be available approximately October 1, 1994. Statements received after the meeting cannot be considered by the panel in preparing their final report.</textblock>
    <textblock>On the second day of the conference, time has been allocated for 5-10 minute formal oral presentations by concerned individuals or organizations. Those individuals or groups wishing to send a representative to contribute during this session must contact Mr. Jerry Elliott by 5 p.m. EST, February 14, 1994, at: Office of Medical Applications of Research, National Institutes of Health, Federal Building, room 618, Bethesda, Maryland 20892, phone (301) 496-1144.</textblock>
    <textblock>The final consensus statement, a document separate from the panel report, will be submitted for publication in professional journals and other publications. The final consensus statement will be available approximately April 1, 1994. Requests for the final consensus statement should be addressed to the NIH Consensus Program Information Service, P.O. Box 2577, Kensington, Maryland 20891, phone 1-800-NIH-OMAR (1-800-644-6627).</textblock>
    <textblock>Dated: January 28, 1994.</textblock>
  </text>
  <usbureau>
    <textblock>National Institutes of Health</textblock>
  </usbureau>
  <doctitle>
    <textblock>Consensus Development Conference on Effects of Corticosteroids for Fetal Maturation on Perinatal Outcomes</textblock>
  </doctitle>
  <signer>
    <textblock>Harold Varmus,</textblock>
  </signer>
  <signjob>
    <textblock>Director, NIH.</textblock>
  </signjob>
  <frfiling>
    <textblock>[FR Doc. 94-2652 Filed 2-4-94; 8:45 am]</textblock>
  </frfiling>
  <billing>
    <textblock>BILLING CODE 4140-01-M</textblock>
  </billing>
</doc>
